| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8714080 | The Journal of Allergy and Clinical Immunology: In Practice | 2018 | 36 Pages |
Abstract
These results suggest that the probability of rapid symptom return in patients with CSU who discontinue treatment with omalizumab can be estimated based on baseline UAS7 and early treatment response.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Marta MD, PhD, Ana MD, PhD, Diego PhD, Nico PhD, Maria-Magdalena PhD, Sam PhD, Valéry PhD,